Download PDF

Other users also viewed these articles

Safety of biologic and synthetic targeted therapies in patients with immune-mediated diseases: data from the BIOBADAGUAY registry Paloma de Abreu; Sonia Cabrera; Darwin Cordovilla; Lourdes Román; Cristina Brunengo; Patricia Melgarejo; Macarena Soto; Vannia Valinotti; Angelica Amarilla; Belem Acevedo; Alexis Pineda; Evelyn Leiva; Paola Pusineri; Sandra Consani; Mariela Zarza; Clyde Parodi; Zoilo Morel; Roger Rolón; Paola Jara; Raquel Aranda; Laura Martínez; Gabriela Ávila;
Reumatol Clin. 2025;21:
Safety and survival associated with biologic therapies: first report of the Biobadaguay on the Paraguayan-Uruguayan registry of adverse events with biologic therapies Paloma de Abreu; Gabriela Ávila-Pedretti; Zoilo Morel; María Isabel Acosta; Sonia Cabrera-Villalba; Patricia Melgarejo; Marcos Franco; Pedro Delgadillo; Lourdes Román; Juan Gabriel Elizaur; Ernesto Paredes; Darwin Octavio Cordobilla; Daniel Palleiro; Miguel Albanese; Julio Mazzoleni;
Reumatol Clin. 2020;16P2:396-404
Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis Alejandro Balsa; Petra Díaz del Campo Fontecha; Lucía Silva Fernández; José Valencia Martín; Virginia Nistal Martínez; Fernando León Vázquez; M. Vanesa Hernández Hernández; Héctor Corominas; Rafael Cáliz Cáliz; José María Aguado García; Gloria Candelas Rodríguez; Nora Ibargoyen Roteta; Arturo Martí Carvajal; M. Nieves Plana Farras; Janet Puñal Riobóo; Hye Sang Park; Yolanda Triñanes Pego; Virginia Villaverde García;
Reumatol Clin. 2023;19:533-48